“We're excited about the momentum we're building. We think we made a good initial splash here,” Enovis CEO Matt Trelotra said recently. mass device.
Wilmington, Delaware-based Enovis, one of the world's largest orthopedic device companies, recently announced a series of positive news.
Mr. Trelotra recently said: mass device He said his strategy for Enovis is to grow through innovation and acquisition.
“Every time we make a new acquisition with new technology, the channel partners of that business are able to sell something new. …What they know and love about us is that we “It means we're going to invest in innovation organically, but we're also going to introduce things faster sometimes through acquisitions,” he said.
Mr. Trerotola had some thoughts about the future of Enovis and the orthopedic device industry. (Comments below have been lightly edited for space and clarity.)
Mass device: Now that you have acquired LimaCorporate, how do you see the potential of 3D printing in orthopedics?
Torerotora: Lima is a true pioneer in the field of metal 3D printing. They developed and used this proprietary material, trabecular titanium, to pioneer 3D printing for the most difficult custom implant situations, i.e. very difficult revision and cancer situations. Developed. In the most demanding implant situations, surgeons turn to Lima as a true pioneer and leader in what is possible with custom design and 3D printing. Lima has also used that ability to design and develop traditional implants that are not personalized, but some of the implants are 3D printed for him, allowing him to cost-effectively create designs and different sizes. It gives you more freedom in terms of what you can create. This gives you some flexibility in what you can do than you would with traditional manufacturing needs.
The mainstream implant products offered in Lima are currently not personalized. However, the use of 3D printing and the increase in custom designs make designs even more complex. There is certainly an opportunity to consider more personalized implants. But right now, the market isn't really paying for personalized implants, so we think we have the ability to pursue that as a future growth option. However, we appreciate the fact that Lima is now focused on a more valuable and practical focus on these custom implants and how to use his 3D printing in design in manufacturing. I like it.
Mass device: About two years ago, Enovis launched ARVIS (Augmented Reality Visualization and Information System) after acquiring Insight Medical. How do you envision this type of software-powered solution improving surgical outcomes?
Torerotora: It's still a competitive market for better implants. We are gaining more market share every year with our better implants. But now we have an additional dimension of enabling technology. I think it's great that a new level of competition is emerging in the market. Additionally, we have historically had great success with Match Point, which enables technology to provide surgeons with pre-operative planning and the ability to provide their own 3D printing equipment that is patient-specific. And now, although ARVIS is initially at a disadvantage, over time there is an opportunity to definitely take it on its shoulders. We are excited about what we bring to the market in terms of the next wave of enabling technology that can support our society. Surgeons improve surgical procedures and collect a lot of data as they do so.
We're working on other interesting things besides frontend and backend. Predictive analytics to plan surgeries, bounce back from different situations, and come up with the best surgery. For this patient in this situation. … Delivering that through an augmented reality guidance system allows surgeons to know what is probably the best plan, but then look at the broader context of the patient at that moment and make thoughtful decisions. , you can do just that, or do something else. And after recording all that data and accumulating it over time and tracking patient success, we can make closed-loop changes in terms of the decisions being made in the surgery and how they affect the outcome. You will be able to do it. I'm really looking forward to seeing what I'll be able to do.
Mass device: What do you think about surgical robotics in orthopedics?
Torerotora: We had the first wave with the giant robots sit on their knees as a smaller player rather than a giant player, and that's where the robots would attack in a big way. We're focusing on next generation technology, which we think is the 2nd, 3rd, and 4th generation that's important here. It has a small footprint, low cost, and the surgery is not very costly or time-consuming. To surgery. We're excited to see how it plays out. We're already in the game working with ARVIS, are excited about the feedback we're getting on it, and are ready to expand the product beyond Match Point and Shoulder as we bring it to market in the not-too-distant future. is being arranged.
Trerotola spoke on the DeviceTalks Weekly podcast last year. Check it out.
